180 Life Sciences’ (ATNF) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of 180 Life Sciences (NASDAQ:ATNF) in a research report released on Friday,Weiss Ratings reports.

180 Life Sciences Stock Down 1.7 %

Shares of ATNF opened at $1.18 on Friday. The stock’s 50 day moving average is $1.44 and its two-hundred day moving average is $2.07. 180 Life Sciences has a twelve month low of $1.10 and a twelve month high of $17.75.

Institutional Investors Weigh In On 180 Life Sciences

An institutional investor recently bought a new position in 180 Life Sciences stock. Rathbones Group PLC purchased a new stake in shares of 180 Life Sciences Corp. (NASDAQ:ATNF) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 69,995 shares of the company’s stock, valued at approximately $127,000. Rathbones Group PLC owned 2.20% of 180 Life Sciences at the end of the most recent quarter. 4.07% of the stock is currently owned by hedge funds and other institutional investors.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.